# Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE

> **NCT06333704** · — · ACTIVE_NOT_RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 4207 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** SPIKEVAX Bivalent BA.1
- **BIOLOGICAL:** SPIKEVAX Bivalent BA.4/5
- **BIOLOGICAL:** SPIKEVAX XBB.1.5
- **BIOLOGICAL:** SPIKEVAX JN.1

## Key facts

- **NCT ID:** NCT06333704
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-10
- **Primary completion:** 2029-03-29
- **Final completion:** 2029-03-29
- **Target enrollment:** 4207 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333704, "Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06333704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*